Unknown

Performance Overview

The financial results for the first quarter of the fiscal year ending March 2027 recorded net sales of 152,383 million yen (up 10.0% YoY), operating income of 14,573 million yen (up 7.4%), and net income of 9,548 million yen (up 3.4%), achieving growth in both revenue and profit. The increase in sales was mainly supported by higher domestic and international sales, while the profit margins were maintained through strict cost management and sales expansion. Segment-wise, the Life Science and Material segments performed especially well. The company aims to continue maintaining solid performance by promoting business expansion and operational efficiency.

Outlook and Impact on Investors

Looking ahead, the company plans to continue expanding sales and profits, with a focus on launching new products and strengthening overseas development. By balancing cost management and R&D investments, long-term growth is expected. For investors, a stable trend of revenue and profit growth combined with proactive business expansion strategies makes the company attractive, raising expectations for stock price increases and dividend growth. It is regarded as a good opportunity for medium- to long-term growth investments.